Defibrillator leads
OmniaSecure™ defibrillation lead
Defibrillator leads
OmniaSecure™ defibrillation lead
The OmniaSecure™ lead is 4.7 French in diameter and catheter-delivered to enable targeted lead placement in the right ventricle.
Description
The world’s smallest defibrillation lead. Built for high reliability.
The OmniaSecure™ MRI SureScan™ defibrillation lead is designed for pacing, sensing, cardioversion, and defibrillation therapies. The lead is an integrated bipolar lead, single coil, with DF4 connection and has been evaluated for safety and efficacy in the Lead EvaluAtion for Defibrillation and Reliability (LEADR) Global Pivotal Trial (NCT04863664).
Features

The world’s smallest defibrillation lead
- 4.7 Fr, 64% smaller than Sprint Quattro™ defibrillator lead1
- May reduce potential lead-related complications, such as vascular occlusion or tricuspid valve complications2–4

Built for high reliability
Durable, lumenless construction
- Built on the proven SelectSecure™ 3830 pacing lead platform5,6
- 98.2% projected 10-year fracture-free rate, based on comprehensive, robust benchtop testing7
Reliable therapy delivery
- 97.5% defibrillation efficacy at implant5
- Stable electricals (sensing, pacing, impedance) through two years5

Catheter delivery enables targeted lead placement
- 97.9% implant success rate with 99.5% of leads placed in desired right ventricular location5
- Full portfolio of catheter shapes to enable targeted placement within the right ventricle
Clinical evidence
97.5% defibrillation efficacy at implant
Primary objective passed, exceeding performance goal, and in line with industry reports5
96.9% freedom from OmniaSecure™ lead-related major complications at two years
Primary safety objective met, exceeding performance goal, and in line with industry reports8
Reliable performance with zero lead fractures and stable electricals
- Zero fractures through all follow-up (17.8 ± 6.0 months) and stable pacing, sensing, and impedance
- 97.9% implant success rate with 99.5% of leads placed in desired right ventricular location8
Cardiac Lead Reliability Model — OmniaSecure™ 10-year results
The novel, small-diameter OmniaSecure™ defibrillation lead is projected to be highly durable.
OmniaSecure™ defibrillation lead predicted to be highly durable with an overall 98.2% fracture-free rate at 10 years9
Specifications


1. 4.7 Fr lead body
2. DF4 connector
3. Fixed helix
4. Steroid-eluting ring
5. Defibrillation coil
6. Integrated bipolar sensing
7. Conductor cable: MP35N
8. Inner insulation: ETFE
9. Inner insulation: silicone
10. Conductor coil: silver cored MP35N
11. Conductor coil insulation: SI polyimide
12. Outer insulation: 55D polyurethane
Implant procedure
Watch to learn more about the OmniaSecure™ lead implant procedure.
Ordering information
Item number | Type | Fixation | Connector | MR Conditional length (cm) | Diameter (Fr) |
3930M64 | Single coil, bipolar | Helix, active fixation | DF4 | 64 | 4.7 |
3930M69 | Single coil, bipolar | Helix, active fixation | DF4 | 69 | 4.7 |
3930M74 | Single coil, bipolar | Helix, active fixation | DF4 | 74 | 4.7 |
3930M79 | Single coil, bipolar | Helix, active fixation | DF4 | 79 | 4.7 |
3930M84 | Single coil, bipolar | Helix, active fixation | DF4 | 84 | 4.7 |
Related links
Related products
- SecureD lead cross-sectional area and volume calculations. September 2021. Medtronic data on file.
- Bharmanee A, Zelin K, Sanil Y, Gupta P, Karpawich PP. Comparative chronic valve and venous effects of lumenless versus stylet-delivered pacing leads in patients with and without congenital heart. Pacing Clin Electrophysiol. 2015;38(11):1343–1350. doi:10.1111/pace.12728.
- Çeliker C, Sayman H, Ersanli M, et al. Diagnosis of abnormal subclavian venous flow by radionuclide venography in patients with permanent pacemaker. Int J Angiol. 1998;7(3):265–267. doi:10.1007/BF01617409.
- Tatum R, Maynes EJ, Wood CT, et al. Tricuspid regurgitation associated with implantable electrical device insertion: A systematic review and meta-analysis. Pacing Clin Electrophysiol. 2021;44(8):1297–1302. doi:10.1111/pace.14287.
- Crossley GH III, Sanders P, Hansky B, et al. Safety, efficacy, and reliability evaluation ofa novel small-diameter defibrillation lead: Global LEADR pivotal trial results. Heart Rhythm. 2024;21(10):1914–1922. doi:10.1016/j.hrthm.2024.04.067.
- Crossley GH, Sanders P, De Filippo P, et al. Rationale and design of the Lead EvaluAtion for Defibrillation and Reliability study: Safety and efficacy of a novel ICD lead design. J Cardiovasc Electrophysiol. 2023;34(2):257–267. doi:10.1111/jce.15747.
- Crossley GH, Mason PK, Hansky B, et al. High predicted durability for the novel small-diameter OmniaSecure defibrillation lead. Heart Rhythm. 2025;22(2):302–310. doi:10.1016/j.hrthm.2024.09.005.
- Sanders P, Mason PK, Hansky B, et al. Sensing and detection performance of the novel, small-diameter OmniaSecure defibrillation lead: in-depth analysis from the LEADR trial. Europace. 2025:euaf062. doi:10.1093/europace/euaf062.
- Crossley GH III, Mason PK, Hansky B, et al. High predicted durability for the novel small-diameter OmniaSecure defibrillation lead. Heart Rhythm. 2025;22(2):302–310. doi:10.1016/j.hrthm.2024.09.005.